OmniAb, Inc. (OABI)
| Market Cap | 750.45M +277.8% |
| Revenue (ttm) | 40.21M +90.6% |
| Net Income | -43.47M |
| EPS | -0.34 |
| Shares Out | 145.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 353,841 |
| Open | 5.10 |
| Previous Close | 5.10 |
| Day's Range | 5.04 - 5.20 |
| 52-Week Range | 1.35 - 5.45 |
| Beta | 1.36 |
| Analysts | Strong Buy |
| Price Target | 8.33 (+61.96%) |
| Earnings Date | Oct 30, 2026 |
About OABI
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company’s technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners’ drug development efforts. Its OmniAb platform’s Biological Intelligence powers the immune systems of its proprietary and engineered transgenic anim... [Read more]
Financial Performance
In 2025, OmniAb's revenue was $18.67 million, a decrease of -29.27% compared to the previous year's $26.39 million. Losses were -$64.78 million, 4.43% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for OABI stock is "Strong Buy." The 12-month stock price target is $8.33, which is an increase of 61.96% from the latest price.
News
OmniAb Slides: Corporate presentation
OmniAb has posted slides in relation to its latest quarterly earnings report, which was published on November 9, 2026.
OmniAb Earnings Call Transcript: Q3 2026
Q3 revenue rose to $4.0M, while FY26 revenue guidance increased to $35M-$39M on milestone strength. The pipeline includes $3B+ in potential milestones, and xPloration is forecast to double revenue in 2027 and again in 2028.
OmniAb Slides: Q3 2026
OmniAb has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 30, 2026.
OmniAb Earnings release: Q3 2026
OmniAb released its Q3 2026 earnings on October 30, 2026, summarizing the period's financial results.
OmniAb Quarterly report: Q3 2026
OmniAb has published its Q3 2026 quarterly earnings report on October 30, 2026.
OmniAb reports Q3 EPS (12c), consensus (13c)
Reports revenue $4M, consensus $3.49M. “Our strong third-quarter 2026 performance reflects our licensing execution and our focus on driving value for our stakeholders within an efficient business mode...
OmniAb raises FY26 revenue view $35M-$39M from $32M-$36M, consensus $35.04M
OmniAb (OABI) revises 2026 financial guidance and now expects revenue to be in the range of $35M to $39M, versus $32M to $36M previously, and costs and operating expenses to…
OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, toda...
OmniAb to Participate in Upcoming Investor Conferences in November
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, toda...
OmniAb Transcript: LD Micro 20th Annual Main Event Conference
The platform pairs transgenic antibody discovery with AI screening, supporting 425 active programs and 34 clinical-stage drugs. xPloration sales are forecast to double in 2027 and again in 2028, while current-year revenue guidance is $32 million–$36 million.
OmniAb to Report Third Quarter 2026 Financial Results on October 30
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, toda...
OmniAb price target raised to $6 from $4 at StoneX
StoneX analyst Robert Wasserman raised the firm’s price target on OmniAb (OABI) to $6 from $4 and keeps a Buy rating on the shares after the company held its first…
OmniAb Transcript: Investor And Anlayst Day 2026
A maturing royalty pipeline, new peptide platform and general-market launch of xPloration broaden growth engines. 2026 guidance was reaffirmed, with xPloration revenue forecast to double annually in 2027 and 2028.
OmniAb Slides: FY 2026
OmniAb has posted slides in relation to its FY 2026 quarterly earnings report, which was published on October 6, 2026.
OmniAb Press release: FY 2026
OmniAb issued a press release on October 6, 2026, disclosing material business information to investors.
OmniAb highlights partner pipeline, xPloration plans, introduces OmniTides
OmniAb (OABI) hosts its Investor & Analyst Day in Emeryville, CA. With a full presentation agenda, the event highlights recent partner developments, the broader roll out of the xPloration platform,…
OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, toda...
OmniAb to Host Investor & Analyst Day on October 6, 2026
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #Antibody--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, ...
OmniAb to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, toda...
OmniAb raises FY26 cash and equivalents view to $49M-$53M vs. $37M-$41M
OmniAb (OABI) raised its FY26 cash and cash equivalents financial guidance following recent technology licensing activity. “Recent business development and licensing activity has enabled us to again r...
OmniAb Raises 2026 Financial Guidance
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, toda...
OmniAb announces collaboration and license agreement with Eli Lilly
OmniAb (OABI) announced a global collaboration and license agreement with Eli Lilly and Company (LLY) for a new ion channel program. The collaboration leverages OmniAb’s technology platform and expert...
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, toda...
OmniAb Slides: Corporate presentation
OmniAb has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
OmniAb reports Q2 EPS (5c), consensus (13c)
Reports Q2 revenue $13.4M, consensus $4.69M. “We are pleased to report a strong quarter and to increase our revenue and cash outlook for 2026 based on continued momentum in our…